ALX Oncology Holdings Inc. Common Stock ALXO
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $4.33 (+108.3% upside)
Key Stats
- Today's Range
- $1.94 – $2.08
- 50-Day Range
- $1.37 – $2.41
- 52-Week Range
- $0.44 – $2.66
- Volume
- 901K shs
- Average Volume
- 1.01 million shs
- Market Cap
- $272.41 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.00
- Price / Sales
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-80,890,000
- Net Margin
- —
- Return on Equity
- -59.40%
- Debt-to-Equity
- 0.07
About ALX Oncology Holdings Inc. Common Stock
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Related Stocks
Compare head-to-head: ALXO vs LLY·ALXO vs JNJ·ALXO vs ABBV·ALXO vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.